| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
HCA Healthcare, Inc.$387.74
+8.86 (+2.34%)
F 16Pipeline Score Tools & Services Β· Commercial
Market Cap
110.77 B
EPS
28.71
P/E Ratio
17.46 $
Value Trade
803.77 M
SEC Financials
Q1 2026Dilution Risk
Revenue
19.11 B
Operating CF
2.01 B
Total Assets
61.45 B
Total Liabilities
61.45 B
Equity
-6.30 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
940.00 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 29, 2026
Overview
Volume
775.64 K
52 Week Range
314.43 - 556.52
% held by Insiders
32.38 %
% held by Institutions
62.52 %
Enterprise Value
161.58 B
Total Shares
221.95 M
Short %
3.57 %
Float Shares
180.22 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for HCA Healthcare, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 β 2026Coverage
Event history 1
TBD
βPublicationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
β | Example Drug | Phase 3 data readout | Phase 3 | β | β | 0% | 0% |
β | Example Drug | Phase 3 data readout | Phase 3 | β | β | 0% | 0% |
β | Example Drug | Phase 3 data readout | Phase 3 | β | β | 0% | 0% |
Drug Pipeline Intelligence
F16
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scoredβ
rNPV / MCap Top 14%
Large Pharma (rank 785 of 912)
Percentile RankHCA Healthcare, Inc. has significant pipeline risk (16/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)Β·9 selling (1 exited)Β·2 unchanged
Hedge Funds invested in HCA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HCA Institutional Ownership Trends
Current Insider %
5.20%
β+0.00%
Current Institutional %
62.40%
β+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-HCA
Jul 14, 2026βΌ -6.9%on this news
HCA Healthcare, Inc. 2nd Quarter 2026 Earnings Conference Call
HCA Healthcare, Inc. has scheduled its 2nd Quarter 2026 Earnings Conference Call for July 24, 2026. The call will be accessible via live audio webcast, allowing investors to listen in on the company's financial performance. The event emphasizes HCA's commitment to investor relations and transparency.
Read more β-HCA
Jul 14, 2026βΌ -6.9%on this newsshared move
HCA Healthcare Previews Second Quarter 2026 Results
HCA Healthcare, Inc. has announced preliminary financial results for the second quarter of 2026, projecting revenues of approximately $20.230 billion, a significant increase from $18.605 billion in the same quarter of 2025. The net income attributable to HCA Healthcare is also expected to reflect positive growth. These results are subject to finalization through the company's accounting procedures.
Read more β-HCA
Jun 29, 2026HCA Healthcare Announces New England Journal of Medicine Study Highlighting Advances in CRISPR-based Therapy for Children
HCA Healthcare has announced a study published in the New England Journal of Medicine that focuses on advancements in CRISPR-based therapy for children. The study highlights significant progress in this innovative treatment approach. However, details regarding the specific findings or implications of the study were not disclosed in the announcement.
Read more β-HCA
May 27, 2026HCA Healthcare Announces Agreement to Acquire The College of Health Care Professions
HCA Healthcare has announced an agreement to acquire The College of Health Care Professions. This acquisition aims to enhance HCA's educational offerings and workforce development. Further details regarding the transaction and its implications for both organizations have not been disclosed.
Read more β-HCA
May 19, 2026HCA Healthcare Colleagues Volunteer More Than 41,800 Hours During Annual Days of Service Initiative
HCA Healthcare colleagues participated in an annual Days of Service initiative, contributing over 41,800 hours of volunteer work. This effort highlights the company's commitment to community service and employee engagement. The initiative not only benefits local communities but also strengthens teamwork among employees.
Read more β-HCA
Apr 30, 2026HCA Healthcare, Inc. to Present at May Conference
HCA Healthcare, Inc. is scheduled to present at the RBC Global Healthcare Conference on May 20, 2026, at 11:30am ET. The presentation will be accessible via a live audio webcast, with materials available on the company's Investor Relations website. HCA Healthcare operates 189 hospitals and approximately 2,600 ambulatory care sites across 19 states and the UK.
Read more β-HCA
Apr 27, 2026HCA Announces Proposed Public Offering of Senior Notes
HCA Healthcare, Inc. has announced a proposed public offering of senior notes through its subsidiary, HCA Inc. The actual terms of the offering will depend on market conditions at the time of pricing. The proceeds from this offering are intended for general corporate purposes, which may include repaying outstanding borrowings.
Read more β-HCA
Apr 27, 2026HCA Healthcare Names Cynthia Cifuentes-Finkel Senior Vice President of Marketing and Corporate Affairs
HCA Healthcare has appointed Cynthia Cifuentes-Finkel as the new Senior Vice President of Marketing and Corporate Affairs. This strategic move is aimed at enhancing the company's marketing efforts and corporate communications. Cifuentes-Finkel's extensive experience is expected to contribute positively to HCA's initiatives.
Read more β-HCA
Apr 27, 2026INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA Announces Proposed PUBLIC Offering of Senior Notes
HCA Healthcare, Inc. announced a proposed public offering of senior notes by its wholly owned subsidiary, HCA Inc. The terms of the notes, including maturity and interest rates, will depend on market conditions at the time of pricing. The net proceeds from the offering are intended for general corporate purposes, potentially including repayment of existing borrowings. Several prominent financial institutions are acting as joint book-running managers for this offering.
Read more β-HCA
Apr 24, 2026βΌ -8.8%on this newsshared move
HCA Healthcare Reports First Quarter 2026 Results
HCA Healthcare reported its first quarter 2026 results, showing a revenue increase of 4.3% to $19.109 billion and a net income rise of 0.6% to $1.620 billion. Despite challenges such as a 42% drop in respiratory-related admissions and adverse weather impacts, the company experienced significant cash flow growth. The board declared a quarterly cash dividend of $0.78 per share, reinforcing its commitment to shareholders.
Read more β-HCA
Apr 24, 2026βΌ -8.8%on this newsshared move
INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare reports FIRST quarter 2026 results Nashville, Tenn.
HCA Healthcare, Inc. has announced its financial and operational results for the first quarter of 2026, ending March 31. The report includes key metrics that compare performance to the first quarter of 2025. Further details regarding the financial performance and metrics have not been disclosed in the provided segment.
Read more β-HCA
Apr 16, 202629 HCA Healthcare Hospitals Recognized on Modern Healthcareβs 100 Top Hospitals Powered by Premier
HCA Healthcare has achieved a significant milestone with 29 of its hospitals being recognized on Modern Healthcare's 100 Top Hospitals list, powered by Premier. This accolade underscores the commitment of HCA to provide high-quality healthcare services. The recognition is expected to bolster the reputation of these hospitals in the healthcare community.
Read more β-HCA
Jan 27, 2026β² +7.1%on this news
INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare reports FOURTH quarter 2025 results AND PROVIDES 2026 GUIDANCE Nashville, Tenn.
HCA Healthcare, Inc. has released its financial results for the fourth quarter of 2025, showing metrics that compare favorably to the same quarter in the previous year. In addition to the quarterly results, the company has also provided guidance for 2026, indicating a positive outlook for its operations in the coming year. This announcement is part of HCA's ongoing efforts to inform investors and the market about its financial health and strategic direction.
Read more β-HCA
Oct 27, 2025INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851
HCA Healthcare, Inc. announced the proposed public offering of senior notes through its subsidiary HCA Inc. The actual terms, including maturity and interest rates, will depend on market conditions at the time of pricing. The proceeds from the offering will be utilized for general corporate purposes, including repaying outstanding borrowings. The offering is subject to an effective shelf registration statement filed with the SEC.
Read more β-HCA
Oct 24, 2025INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare reports THIRD quarter 2025 results RAISES 2025 Guidance Nashville, Tenn.
HCA Healthcare, Inc. has announced its financial and operational results for the third quarter of 2025, which ended on September 30. The results display an improvement compared to the previous year, prompting the company to raise its guidance for the full year of 2025. This is noted as a positive indicator of the company's future performance and financial health.
Read more β-HCA
Jul 25, 2025INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare reports SECOND quarter 2025 results RAISES 2025 Guidance Nashville, Tenn.
HCA Healthcare, Inc. announced its financial and operational results for the second quarter of 2025, highlighting growth in key metrics. The company also raised its guidance for the full year, suggesting optimism about future performance. These results reflect a positive trend compared to the same period in the previous year.
Read more β-HCA
Jul 11, 2025INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA HEALTHCARE APPOINTS JOHN W. CHIDSEY
HCA Healthcare has appointed John W. Chidsey, III as an independent director, effective July 15, 2025, increasing the board's membership to ten. Chidsey, who has served as global CEO of Subway and CEO of Burger King Holdings, brings a wealth of experience in corporate strategy and leadership. He will also participate in key committees, emphasizing his importance to the company's governance. His background includes significant roles in both public and private companies, which is expected to add valuable insights to HCA Healthcare's initiatives.
Read more β-HCA
Apr 25, 2025INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare reports FIRST quarter 2025 results Nashville, Tenn.
HCA Healthcare, Inc. has released its financial and operational results for the first quarter of 2025, ending March 31, 2025. The report highlights various key metrics but does not present specific figures or significant developments in the text provided. Further details regarding percentage changes and important performance indicators are expected to be included in the full report. This announcement follows the company's ongoing efforts to communicate its financial health to stakeholders.
Read more β-HCA
Jan 24, 2025INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare reports FOURTH quarter 2024 results AND PROVIDES 2025 GUIDANCE Nashville, Tenn.
HCA Healthcare reported its fourth quarter results for 2024, highlighting a revenue increase to $18.285 billion compared to $17.303 billion in the same quarter of 2023. The company faced challenges, including financial losses tied to hurricanes and a decrease in net income. Nonetheless, HCA's operational performance showed improvements with rising admissions and an overall increase in annual revenues, as well as optimistic guidance for 2025. They also announced a new share repurchase program and declared a quarterly cash dividend, demonstrating ongoing financial strength.
Read more β-HCA
Oct 25, 2024βΌ -8.9%on this news
INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare reports THIRD quarter 2024 results Nashville, Tenn.
HCA Healthcare, Inc. reported its financial results for the third quarter of 2024, indicating a revenue growth to $17.487 billion and a net income rise to $1.270 billion. However, the company faced challenges due to Hurricane Helene, resulting in estimated losses of $50 million in the quarter and anticipated ongoing losses between $200 to $300 million. Despite these setbacks, HCA remains committed to its operational guidance for 2024 and has positive indicators such as increased admissions.
Read more β-HCA
Jul 23, 2024INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA HEALTHCARE REPORTS SECOND QUARTER 2024 RESULTS RAISES 2024 GUIDANCE Nashville, Tenn.
HCA Healthcare announced its financial results for the second quarter of 2024, showing a substantial increase in revenues and net income compared to the same period in 2023. The company's revenues reached $17.492 billion, marking an increase from $15.861 billion last year, while net income rose to $1.461 billion or $5.53 per diluted share. In addition to these positive results, HCA has raised its 2024 guidance for both revenues and net income, reflecting strong operational performance and increasing demand for its services. The board also declared a quarterly cash dividend of $0.66 per share to stockholders.
Read more β-HCA
Apr 26, 2024INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA HEALTHCARE REPORTS FIRST QUARTER 2024 RESULTS Nashville, Tenn.
HCA Healthcare reported robust financial results for the first quarter of 2024, with revenues totaling $17.339 billion, marking an increase from the previous year. Net income also saw a significant rise to $1.591 billion, supported by broad-based volume growth. The company experienced increases in same facility admissions and emergency visits, contributing to positive operational metrics. Despite strong performance, HCA faces challenges such as high levels of debt and potential operational cost increases due to market conditions.
Read more β-HCA
Jan 30, 2024β² +5.2%on this news
INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA HEALTHCARE REPORTS FOURTH QUARTER 2023 RESULTS AND PROVIDES 2024 GUIDANCE BILL RUTHERFORD TO RETIRE AND M
HCA Healthcare, Inc. reported strong financial results for the fourth quarter of 2023, with revenues reaching $17.303 billion and an Adjusted EBITDA of $3.618 billion. The company announced a decline in net income compared to the previous year but noted significant year-on-year revenue growth. Additionally, Bill Rutherford will retire as CFO, with Mike Marks appointed to succeed him. HCA also provided guidance for 2024, anticipating revenues between $67.75 billion and $70.25 billion amidst various economic uncertainties.
Read more β-HCA
Nov 9, 2023INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA HEALTHCARE PROVIDES BUSINESS OUTLOOK AHEAD OF INVESTOR DAY Nashville, Tenn.
HCA Healthcare is hosting its Investor Day, during which it will discuss its financial performance, operational strategies, and long-term growth targets. The company is expecting its 2024 financial results to align with these targets, although there are uncertainties that may affect actual performance. HCA also acknowledges potential risks, including changes in patient volumes and economic conditions, which might impact its operations and profitability moving forward.
Read more β-HCA
Oct 24, 2023INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA HEALTHCARE REPORTS THIRD QUARTER 2023 RESULTS REVISES 2023 GUIDANCE Nashville, Tenn.
HCA Healthcare reported strong financial results for the third quarter of 2023, with revenues of $16.213 billion, marking an increase from the previous year's $14.971 billion. However, the company's Valesco physician staffing joint venture underperformed, which negatively impacted overall results. The adjusted EBITDA experienced a slight decrease, totaling $2.880 billion compared to $2.902 billion in the third quarter of 2022. HCA has revised its full-year guidance, slightly adjusting revenue and net income expectations, while announcing a quarterly cash dividend of $0.60 per share.
Read more β-HCA
Jul 27, 2023INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA HEALTHCARE REPORTS SECOND QUARTER 2023 RESULTS RAISES 2023
HCA Healthcare announced its second quarter 2023 financial results, reporting revenues of $15.861 billion, up from $14.820 billion in the same period last year. Net income for the quarter also increased to $1.193 billion or $4.29 per diluted share. The company has revised its 2023 guidance upwards, suggesting a strong outlook for the remainder of the year. Increased same facility admissions and higher capital expenditures were noted as contributing factors to these positive results.
Read more β-HCA
May 26, 2023HCA HEALTHCARE, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Financial Statements: Consolidated Income Statements for the years ended
HCA Healthcare, Inc. published its consolidated financial statements, reporting a revenue increase to $60.233 billion for the year 2022. The independent auditor, Ernst & Young LLP, provided an unqualified opinion on the financial statements, confirming their fair presentation in accordance with U.S. accounting standards. The audit also highlighted complex areas such as revenue recognition and professional liability claims reserves, emphasizing the significant judgment required in these estimates. Overall, the financial statements reflect a positive operational performance amid potential risks identified in the critical audit matters.
Read more β-HCA
Apr 21, 2023INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA HEALTHCARE REPORTS FIRST QUARTER 2023 RESULTS REVISES 2023
HCA Healthcare has released its financial results for the first quarter of 2023, showcasing a robust revenue increase to $15.591 billion, up from $14.945 billion in 2022. The net income for the quarter also saw a rise, totaling $1.363 billion. However, the company faced losses related to facility sales and a decrease in revenue per admission. Revised guidance for the year reflects expectations of continued growth despite economic challenges.
Read more β-HCA
Jan 27, 2023INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA HEALTHCARE REPORTS FOURTH QUARTER 2022 RESULTS AND PROVIDES 2023 GUIDANCE Nashville, Tenn.
HCA Healthcare reported its fourth-quarter 2022 results with a revenue of $15.497 billion, up from $15.064 billion in Q4 2021. Net income for the quarter rose to $2.081 billion, reflecting solid financial performance despite some challenges. The company announced guidance for 2023, projecting revenue between $61.5 billion and $63.5 billion and adjusted EBITDA between $11.8 billion and $12.4 billion. However, Hurricane Ian's aftermath affected operations, leading to additional expenses. Overall, the company's strong cash flows and share repurchase program demonstrate positive financial health.
Read more β-HCA
Oct 21, 2022βΌ -5.7%on this newsshared move
INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA HEALTHCARE REPORTS THIRD QUARTER 2022 RESULTS Nashville, Tenn.
HCA HEALTHCARE REPORTS THIRD QUARTER 2022 RESULTS Nashville, Tenn., October 21, 2022 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the third quarter ended September 30, 2022. Key third quarter metrics (all percentage changes compare 3Q 202
Read more β-HCA
Jul 22, 2022β² +11.4%on this news
INVESTOR CONTACT: FOR IMMEDIATE RELEASE MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare Reports Second Quarter 2022 Results Nashville, Tenn.
HCA Healthcare Reports Second Quarter 2022 Results Nashville, Tenn., July 22, 2022 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2022. Key second quarter metrics (all percentage changes compare 2Q 2022 to
Read more β-HCA
Apr 22, 2022βΌ -21.8%on this news
INVESTOR CONTACT: FOR IMMEDIATE RELEASE MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare Reports First Quarter 2022 Results Revises 2022 Guidance Nashville, Tenn.
HCA Healthcare Reports First Quarter 2022 Results Revises 2022 Guidance Nashville, Tenn., April 22, 2022 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the first quarter ended March 31, 2022. Key first quarter metrics (all percentage chang
Read more β-HCA
Jan 27, 2022INVESTOR CONTACTS: MEDIA CONTACT: Mark Kimbrough, Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare Reports Fourth Quarter 2021 Results and Provides 2022 Guidance Company Increa
HCA Healthcare Reports Fourth Quarter 2021 Results and Provides 2022 Guidance Company Increases Capital Spending, Authorizes Additional Share Repurchase Program and Increases Quarterly Dividend Nashville, Tenn., January 27, 2022 HCA Healthcare, Inc. (NYSE: HCA) today announced
Read more β-HCA
Oct 22, 2021INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare Reports Third Quarter 2021 Results; Revises 2021 Guidance Nashville, Tenn.
HCA Healthcare Reports Third Quarter 2021 Results; Revises 2021 Guidance Nashville, Tenn., October 22, 2021 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the third quarter ended September 30, 2021. Key third quarter metrics (all percentag
Read more β-HCA
Jul 27, 2021INVESTOR CONTACT: Mark Kimbrough 615-344-2688 MEDIA CONTACT: Harlow Sumerford 615-344-1851 HCA Healthcare Appoints Hugh F. Johnston as New Independent Director
HCA Healthcare Appoints Hugh F. Johnston as New Independent Director NASHVILLE, Tenn., July 27, 2021 HCA Healthcare, Inc. (NYSE: HCA) today announced that its board of directors has appointed Hugh F. Johnston as an independent director, effective September 1, 2021. With his addi
Read more β-HCA
Jul 20, 2021β² +14.4%on this news
INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare Reports Second Quarter 2021 Results; Raises 2021 Guidance Nashville, Tenn.
HCA Healthcare Reports Second Quarter 2021 Results; Raises 2021 Guidance Nashville, Tenn., July 20, 2021 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2021. Key second quarter metrics (all percentage chan
Read more β-HCA
Apr 22, 2021INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare Reports First Quarter 2021 Results Revises 2021 Guidance Nashville, Tenn.
HCA Healthcare Reports First Quarter 2021 Results Revises 2021 Guidance Nashville, Tenn., April 22, 2021 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the first quarter ended March 31, 2021. Key first quarter metrics (all percentage chang
Read more β-HCA
Feb 2, 2021INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare Reports Fourth Quarter 2020 Results and Provides 2021 Guidance Company Reinstates and Increa
HCA Healthcare Reports Fourth Quarter 2020 Results and Provides 2021 Guidance Company Reinstates and Increases Quarterly Dividend; Resumes Share Repurchase Program and Increases Authorization Nashville, Tenn., February 2, 2021 HCA Healthcare, Inc. (NYSE: HCA) today announced
Read more β-HCA
Oct 26, 2020INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare Reports Third Quarter 2020 Results Nashville, Tenn.
HCA Healthcare Reports Third Quarter 2020 Results Nashville, Tenn., October 26, 2020 HCA Healthcare, Inc. (NYSE: HCA) today announced its completed financial and operating results for the third quarter ended September 30, 2020. Key third quarter metrics (all percentage changes
Read more β-HCA
Oct 8, 2020INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare Previews 2020 Third Quarter Results; Will Return Approximately $6 Billion in CARES Act Fundi
HCA Healthcare Previews 2020 Third Quarter Results; Will Return Approximately $6 Billion in CARES Act Funding Nashville, Tenn., October 8, 2020 HCA Healthcare, Inc. (NYSE: HCA) today announced preliminary financial and operating results for its third quarter ended September 30,
Read more β-HCA
Jul 22, 2020INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare Reports Second Quarter 2020 Results Nashville, Tenn.
HCA Healthcare Reports Second Quarter 2020 Results Nashville, Tenn., July 22, 2020 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2020. Key second quarter metrics (all percentage changes compare 2Q 2020 to
Read more β-HCA
Apr 21, 2020INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare Reports First Quarter 2020 Results Addresses COVID-19 Uncertainty Nashville, Tenn.
HCA Healthcare Reports First Quarter 2020 Results Addresses COVID-19 Uncertainty Nashville, Tenn., April 21, 2020 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the first quarter ended March 31, 2020. The Company also announced that it has
Read more β-HCA
Feb 11, 2020INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Harlow Sumerford 615-344-2688 615-344-1851
HCA ANNOUNCES PROPOSED PUBLIC OFFERING OF SENIOR NOTES NASHVILLE, Tenn., February 11, 2020 HCA Healthcare, Inc. (NYSE: HCA) today announced that its wholly-owned subsidiary, HCA Inc., proposes to offer $1.0 billion aggregate principal amount of senior notes due 2030, subject to
Read more β-HCA
Jan 28, 2020INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Harlow Sumerford 615-344-2688 615-344-1851 HCA Reports Fourth Quarter 2019 Results and Provides 2020 Guidance Board Authorizes Additional $2 Billion S
HCA Reports Fourth Quarter 2019 Results and Provides 2020 Guidance Board Authorizes Additional $2 Billion Share Repurchase Program and Increases Quarterly Dividend Nashville, Tenn., January 28, 2020 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating resu
Read more β-HCA
Oct 29, 2019INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Ed Fishbough 615-344-2688 615-344-2810 HCA Reports Third Quarter 2019 Results Nashville, Tenn.
HCA Reports Third Quarter 2019 Results Nashville, Tenn., October 29, 2019 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the third quarter ended September 30, 2019. Key third quarter metrics (all percentage changes compare 3Q 2019 to 3Q 201
Read more β-HCA
Jul 30, 2019INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Ed Fishbough 615-344-2688 615-344-2810 HCA Reports Second Quarter 2019 Results Updates 2019 Guidance Nashville, Tenn.
HCA Reports Second Quarter 2019 Results Updates 2019 Guidance Nashville, Tenn., July 30, 2019 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2019. Key second quarter metrics (all percentage changes compare
Read more β-HCA
Apr 30, 2019INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Ed Fishbough 615-344-2688 615-344-2810 HCA Reports First Quarter 2019 Results Nashville, Tenn.
HCA Reports First Quarter 2019 Results Nashville, Tenn., April 30, 2019 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the first quarter ended March 31, 2019. Key first quarter metrics (all percentage changes compare 1Q 2019 to 1Q 2018 unle
Read more β-HCA
Feb 21, 2019news FOR IMMEDIATE RELEASE INVESTOR CONTACT: Mark Kimbrough 615-344-2688 MEDIA CONTACT: Ed Fishbough 615-344-2810
HCA HEALTHCARE APPOINTS MEG CROFTON AS NEW INDEPENDENT DIRECTOR NASHVILLE, Tenn., February 21, 2019 HCA Healthcare (NYSE: HCA) today announced that its board of directors has appointed Meg Crofton as an independent director, effective March 1, 2019. With her addition, HCA Healt
Read more β-HCA
Jan 29, 2019INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Ed Fishbough 615-344-2688 615-344-2810 HCA Reports Fourth Quarter 2018 Results and Provides 2019 Guidance Board Authorizes Additional $2 Billion Share
HCA Reports Fourth Quarter 2018 Results and Provides 2019 Guidance Board Authorizes Additional $2 Billion Share Repurchase Program and Increases Quarterly Dividend Nashville, Tenn., January 29, 2019 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating resu
Read more β-HCA
Jan 17, 2019HCA Announces Proposed Public Offering of Senior Notes NASHVILLE, Tenn. (BUSINESS WIRE) HCA Healthcare, Inc. (NYSE: HCA) today announced that its wholly owned subsidiary, HCA Inc., proposes to offer $1.0 billion aggregat
HCA Announces Proposed Public Offering of Senior Notes NASHVILLE, Tenn. (BUSINESS WIRE) HCA Healthcare, Inc. (NYSE: HCA) today announced that its wholly owned subsidiary, HCA Inc., proposes to offer $1.0 billion aggregate principal amount of senior notes, subject to market and o
Read more β-HCA
Oct 30, 2018INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Ed Fishbough 615-344-2688 615-344-2810 HCA Reports Third Quarter 2018 Results Nashville, Tenn.
HCA Reports Third Quarter 2018 Results Nashville, Tenn., October 30, 2018 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the third quarter ended September 30, 2018. Key third quarter metrics (all percentage changes compare 3Q 2018 to 3Q 201
Read more β-HCA
Sep 10, 2018news FOR IMMEDIATE RELEASE INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Ed Fishbough 615-344-2688 615-344-2810 HCA HEALTHCARE CHAIRMAN AND CEO MILTON JOHNSON TO RETIRE; CURRENT PRESIDENT AND COO SAM HAZEN TO BECOME CE
HCA HEALTHCARE CHAIRMAN AND CEO MILTON JOHNSON TO RETIRE; CURRENT PRESIDENT AND COO SAM HAZEN TO BECOME CEO Nashville, Tenn., September 10, 2018 -- The board of directors of HCA Healthcare (NYSE: HCA) today announced that it has approved the following: Johnson, a 36-year veter
Read more β-HCA
Jul 25, 2018INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Ed Fishbough 615-344-2688 615-344-2810 HCA Reports Second Quarter 2018 Results Nashville, Tenn.
HCA Reports Second Quarter 2018 Results Nashville, Tenn., July 25, 2018 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2018. Key second quarter metrics (all percentage changes compare 2Q 2018 to 2Q 2017 unl
Read more β-HCA
May 1, 2018INVESTOR CONTACT: MEDIA CONTACT: Mark Kimbrough Ed Fishbough 615-344-2688 615-344-2810 HCA Reports First Quarter 2018 Results Nashville, Tenn.
HCA Reports First Quarter 2018 Results Nashville, Tenn., May 1, 2018 HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the first quarter ended March 31, 2018. Key first quarter metrics (all percentage changes compare 1Q 2018 to 1Q 2017 unless
Read more βCompetitive Position
How HCA ranks across every disease it competes inCompetitive Position is a premium feature
See how HCA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial